Plain-English translation of NCT07430319 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Psoriasis research guide →This real-world study is looking at patients with psoriasis who are being treated with guselkumab (Tremfya), a biologic medication that reduces skin inflammation. Researchers want to understand what happens in everyday practice when doctors space out the injections further apart for patients who respond very well to treatment. The goal is to see if longer intervals between doses work safely while keeping people's skin clear and improving their quality of life.
Previous research showed that some patients who respond extremely well to this medication might be able to go longer between injections, potentially reducing how often they need treatment. However, there are still questions about whether this approach works in real-world situations and how it affects patients' long-term outcomes and well-being.
You likely qualify if…
You likely don't qualify if…
You would continue taking your regular medication injections on the spaced-out schedule your doctor has already recommended, while researchers collect information about how your skin responds over time. The study involves tracking your disease severity scores and quality-of-life measurements at routine clinic visits. This is an observational study, meaning researchers are watching and documenting what happens with your current treatment plan rather than asking you to change anything.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
France